Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.42 |
| ▸ | PPIB | P23284 | 1/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | PPID | Q08752 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL274132 | 0.98 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1NPC1PKMNFKB1 | |
| SCHEMBL5062207 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1NPC1PKMNFKB1 | |
| SCHEMBL68412 | 0.88 | L3MBTL1 (0.50) | SMN1; SMN2L3MBTL1NPC1PKMNFKB1 | |
| SCHEMBL11628393 | 0.86 | YWHAG (0.42) | SMN1; SMN2L3MBTL1CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL8852497 | 0.84 | TSHR (0.48) | L3MBTL1NPC1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL11630463 | 0.84 | PPID (0.51) | L3MBTL1ALDH1A1PPIBPPIAPPID | |
| SCHEMBL1068218 | 0.84 | CYP4F2 (0.55) | SMN1; SMN2ALDH1A1CYP4Z1MAOAMAOB | |
| SCHEMBL5725282 | 0.83 | LOXL2 (0.49) | SMN1; SMN2L3MBTL1NPC1PKMNFKB1 | |
| SCHEMBL11633043 | 0.83 | L3MBTL1 (0.53) | L3MBTL1NPC1RAB9AALDH1A1MAPK1 | |
| SCHEMBL13009567 | 0.83 | NPC1 (0.46) | SMN1; SMN2L3MBTL1NPC1PKMNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-RE48731-E1 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2021-09-14 | — | — | US | disclosed |
| CN-108047142-B | Heteroaryl compounds and uses thereof | 西建卡尔有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| EP-3201207-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| EP-3722296-A2 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20200148937-A1 | INHIBITING HYDROCARBON HYDRATE AGGLOMERATION | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2020-05-14 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| WO-2000024744-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
| CN-1226895-A | Amino acid derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 1999-08-25 | — | — | CN | disclosed |
| EP-0910573-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997046577-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
| US-5475106-A | Agonist for cholecystokinin and gastrin receptors; nervous system, gastrointestinal disorders | RHONE-POULENC RORER S.A. (FR) | 1995-12-12 | — | — | US | disclosed |
| US-5382590-A | Gastrointestinal disorders and nervous system disorders | RHONE-POULENC RORER S.A. (FR) | 1995-01-17 | — | — | US | disclosed |
| EP-0052296-B1 | GLUTAMINE DERIVATIVES USABLE FOR CURING IMMUNE DISEASES, METHODS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING SAID DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1984-06-27 | — | — | EP | disclosed |
| US-4440940-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
| US-4439448-A | IMMUNOMODULATING ACTIVITY | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1984-03-27 | — | — | US | disclosed |
| EP-0052296-A1 | Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148937-A1 | INHIBITING HYDROCARBON HYDRATE AGGLOMERATION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AHR, SHH | SMN1; SMN2 4775/4885L3MBTL1 2733/4885NPC1 423/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SMN1; SMN2 4194/4885L3MBTL1 2337/4885NPC1 3346/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | SMN1; SMN2 2891/4885L3MBTL1 2144/4885NPC1 4118/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | SMN1; SMN2 4194/4885L3MBTL1 2337/4885NPC1 3346/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | SMN1; SMN2 3283/4885L3MBTL1 3610/4885NPC1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.